Sitagliptin-d6

CAT: 0804-HY-13749S3Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-13749S3Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Sitagliptin-d6 (MK-0431-d6) is deuterium labeled Sitagliptin (HY-13749) . Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
CAS Number
[1133211-99-0]
Product Name Alternative
MK-0431-d6
UNSPSC
12352005
Target
Dipeptidyl Peptidase; Endogenous Metabolite; ERK; GLP Receptor; Isotope-Labeled Compounds; PKA
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Others; Stem Cell/Wnt; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Metabolic Disease
Smiles
FC(F)(C1=NN=C2N1C([2H])([2H])C([2H])([2H])N(C(C[C@H](N)CC3=C(C=C(C(F)=C3)F)F)=O)C2([2H])[2H])F
Molecular Formula
C16H9D6F6N5O
Molecular Weight
413.35
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Beconi, M.G., et al. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos, 2007. 35 (4) : p. 525-32.|[3]Kim, S.J., et al., Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes, 2008. 57 (5) : p. 1331-9.|[4]Sangle, G.V., et al., Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a GLP-1 secretagogue. Endocrinology, 2012. 153 (2) : p. 564-73.|[5]Kim, S.J., et al., Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes, 2009. 58 (3) : p. 641-51.|[6]Thomas, L., et al. (R) -8- (3-amino-piperidin-1-yl) -7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008 Apr;325 (1) :175-82.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-13749-01Sitagliptin
HY-147401-01Sitagliptin fenilalanil
HY-13749A-01Sitagliptin (phosphate)
HY-13749ESitagliptin (hydrochloride)
HY-13749R-01Sitagliptin (Standard)
HY-13749D-01(Rac) -Sitagliptin
HY-13749S2Sitagliptin-d4
HY-13749AS-01Sitagliptin-d4 (phosphate)
HY-131250-01N-Boc-Sitagliptin
HY-13749AR-01Sitagliptin (phosphate) (Standard)

Alternative Products

CatalogName
M14629-01Sitagliptin
MBS3616294-01Sitagliptin phosphate
MBS5806580Sitagliptin fenilalanil

Popular Products